XML 63 R50.htm IDEA: XBRL DOCUMENT
v3.20.2

Royalty Purchase Agreements - Aronora (Details) $ in Thousands |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | ---
Apr. 07, 2019 USD ($) item | Sep. 30, 2019 USD ($) | Sep. 30, 2020 USD ($) | Sep. 30, 2020 USD ($) | Sep. 30, 2019 USD ($) | Dec. 31, 2019 USD ($)
Agreements |  |  |  |  |  |  |
Long-term royalty receivables |  |  | $ 34,375 | $ 34,375 |  | $ 34,375 | [1]
Contingent consideration under royalty purchase agreements |  |  | 75 | 75 |  | 75 | [1]
Payments of contingent consideration |  |  | $ 0 | 0 |  |  |
Changes in estimated fair value of contingent consideration |  |  |  | 0 |  |  |
Impairment of long-term royalty receivable |  |  |  | 0 |  | $ 0 |
Payments to acquire milestones and royalties |  |  |  |  | $ 19,300 |  |
Proceeds from issuance of long-term debt |  |  |  |  | $ 9,500 |  |
Royalty Purchase Agreement | Aronora |  |  |  |  |  |  |
Agreements |  |  |  |  |  |  |
Number of drug candidates | item | 5 |  |  |  |  |  |
Non-royalties to be received (as a percent) | 10.00% |  |  |  |  |  |
Future non-royalty payments to be received (as a percent) | 5.00% |  |  |  |  |  |
Multiplier for cumulative amount of consideration paid | item | 2 |  |  |  |  |  |
Upfront payment | $ 6,000 |  |  |  |  |  |
Threshold amount of cumulative royalties on net sales per product | 250,000 |  |  |  |  |  |
Long-term royalty receivables | 9,000 |  |  |  |  |  |
Contingent consideration under royalty purchase agreements | 3,000 |  |  |  |  |  |
Payments of contingent consideration |  | $ 3,000 |  |  |  |  |
Impairment of long-term royalty receivable |  |  |  | $ 0 |  |  |
Aggregate milestones payments per product | 85,000 |  |  |  |  |  |
Royalty Purchase Agreement | Aronora | Silicon Valley Bank Loans |  |  |  |  |  |  |
Agreements |  |  |  |  |  |  |
Upfront payment | $ 3,000 |  |  |  |  |  |
Royalty Purchase Agreement | Aronora | Bayer Products |  |  |  |  |  |  |
Agreements |  |  |  |  |  |  |
Number of drug candidates | item | 3 |  |  |  |  |  |
Number of drug candidates subject to exclusive license option | item | 1 |  |  |  |  |  |
Royalties on net sales of products (as a percent) | 100.00% |  |  |  |  |  |
Non-royalties to be received (as a percent) | 10.00% |  |  |  |  |  |
Contingent future cash payment for each product | $ 1,000 |  |  |  |  |  |
Potential future cash payments | $ 3,000 |  |  |  |  |  |
Royalty Purchase Agreement | Aronora | Non-Bayer Products |  |  |  |  |  |  |
Agreements |  |  |  |  |  |  |
Number of drug candidates | item | 2 |  |  |  |  |  |
Non-royalties to be received (as a percent) | 10.00% |  |  |  |  |  |
[1] | The consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromIssuanceOfLongTermDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of drug candidates subject to exclusive license option. + References No definition available. + Details
Name: | xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of drug candidates under the terms of the agreement. + References No definition available. + Details
Name: | xoma_AgreementDrugCandidatesNumber
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Multiplier used in determining change in payment percentage. + References No definition available. + Details
Name: | xoma_AgreementPaymentPercentageFactor
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Changes in estimated fair value of contingent consideration. + References No definition available. + Details
Name: | xoma_ChangesInEstimatedFairValueOfContingentConsideration
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contingent consideration under royalty purchase agreements. + References No definition available. + Details
Name: | xoma_ContingentConsiderationUnderRoyaltyPurchaseAgreements
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contingent future cash payments. + References No definition available. + Details
Name: | xoma_ContingentFutureCashPayments
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of contingent future cash payment for each product. + References No definition available. + Details
Name: | xoma_ContingentFutureCashPaymentsPerProduct
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Threshold amount of cumulative royalties on net sales per product under the terms of the agreement + References No definition available. + Details
Name: | xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate amount of write-downs for impairments recognized during the period for long term royalty receivable assets. + References No definition available. + Details
Name: | xoma_ImpairmentOfLongTermRoyaltyReceivable
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Long-term royalty receivable non current. + References No definition available. + Details
Name: | xoma_LongTermRoyaltyReceivableNonCurrent
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Maximum amount of aggregate tiered milestone payments to be made under the terms of the agreement. + References No definition available. + Details
Name: | xoma_MilestonesPaymentsToAggregateAmountOfPerProduct
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments of contingent consideration. + References No definition available. + Details
Name: | xoma_PaymentsOfContingentConsideration
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments related to purchase of royalty rights. + References No definition available. + Details
Name: | xoma_PaymentsRelatedToPurchaseOfRoyaltyRights
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Purchased percentage of non-royalties on net sales of products. + References No definition available. + Details
Name: | xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts
Namespace Prefix: | xoma_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Future non-royalty payments to be received as a percent upon receipt of specified cumulative amount of consideration paid. + References No definition available. + Details
Name: | xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage
Namespace Prefix: | xoma_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Purchased percentage of royalties on net sales of products. + References No definition available. + Details
Name: | xoma_PurchasedPercentageOfRoyaltiesOnNetSalesOfProducts
Namespace Prefix: | xoma_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Upfront payment. + References No definition available. + Details
Name: | xoma_UpfrontPayment
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_AronoraIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_BayerProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_NonBayerProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |